(170 days)
Not Found
No
The description focuses on a chemical reaction and current measurement to calculate glucose concentration, with no mention of AI or ML terms or concepts.
No.
The device is for monitoring glucose levels, not for treating or preventing diabetes.
No
The device is explicitly stated as "not intended for the diagnosis of or screening for diabetes mellitus." It is intended as an aid in monitoring the effectiveness of a diabetes control program.
No
The device description explicitly mentions a "meter" and "test strip," which are hardware components essential for the device's function.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states it's for the "quantitative measurement of glucose in whole blood." This involves testing a sample taken from the body (whole blood) outside of the body (in vitro) to provide diagnostic information (glucose levels).
- Device Description: The description explains a chemical reaction on a test strip with whole blood, which is a hallmark of many IVD tests.
- Anatomical Site: It specifies "whole blood" as the sample source, which is a biological specimen tested in vitro.
The fact that it's used to monitor diabetes control programs further reinforces its role as an IVD, providing information to aid in managing a medical condition.
N/A
Intended Use / Indications for Use
The BTg Smartest Glucose test system is intended for use in the quantitative measurement of glucose in whole blood. It is intended for use by healthcare professionals and people with diabetes mellitus at home as an aid in monitoring the effectiveness of a diabetes control program. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates.
Product codes
NBW, JJX
Device Description
A chemical reaction between glucose in whole blood and the chemicals on the test strip produce a current. The meter measures the current and the meter calculates glucose concentrations from the current produced in the reaction.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not intended for use on neonates.
Intended User / Care Setting
healthcare professionals and people with diabetes mellitus at home
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Not Found
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.1345 Glucose test system.
(a)
Identification. A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.(b)
Classification. Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
0
DEC 1 8 2003
5. 510(k) SUMMARY (Per 21CFR807.92)
June 27, 2003
Submitter Information Contact Person: Debbie Cheng Phone Number: 886-4-23508198 or 973-762-0516 (US) FAX Number: 886-4-23508199
Trade Name: BTg Smartest Glucose Test System
Common Name: Glucose test system
Panel: Clinical Chemistry 75
Product Code: NBW
Device Classification: Class II
Intended Use
The BTg Smartest Glucose test system is intended for use in the quantitative measurement of glucose in whole blood. It is intended for use by healthcare professionals and people with diabetes mellitus at home as an aid in monitoring the effectiveness of a diabetes control program. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates.
Device Description
A chemical reaction between glucose in whole blood and the chemicals on the test strip produce a current. The meter measures the current and the meter calculates glucose concentrations from the current produced in the reaction.
Predicate Device Information- Statement of Substantial Equivalence The BTg Smartest Glucose Test System is substantially equivalent to the Bayer Elite with the Ascensia Elite test strips, 510(k) Number: K991242.
1
| ELITE | BTG | |
|---|---|---|
| Similarities | 1. Intended use: Monitors Glucose using whole blood. | 1. Intended use: Monitors Glucose using whole blood. |
| 2. Directly displays results without requiring calculation. | 2. Directly displays results without requiring calculation. | |
| 3. Test Principle: Principle includes measuring glucose by measuring a current produced by a chemical reaction. | 3. Test Principle: Principle includes measuring glucose by measuring a current produced by a chemical reaction. | |
| 4. Test Principle: Uses glucose oxidase reaction. | 4. Test Principle: Uses glucose oxidase reaction. | |
| 5. Measuring Range: 20 to 600 mg/dL. | 5. Measuring Range: 20 to 600 mg/dL. | |
| ELITE | BTG | |
| Differences | 1. Size: Meter is 97.8 x56 x14.5 mm. | 1. Size: Meter is 115x 44 x 21, which is longer and slimmer, but thicker than the ELITE. |
| 2. Measuring time: 30 seconds. | 2. Measuring time: 15 seconds. |
.
:
Similarities and Differences (Predicate and Smartest BTG Glucose)
2
Image /page/2/Picture/1 description: The image shows the seal of the Department of Health & Human Services - USA. The seal is circular and contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. In the center of the seal is an abstract image of an eagle.
DEC 1 8 2003
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Ms. Debbie Cheng BT Medical 6F-5 #210 38th Road Taichung Industrial Park Taichung CHINA (TAIWAN)
Re: K032029
Trade/Device Name: BTg Smartest Glucose Test System Regulation Number: 21 CFR 862.1345 Regulation Name: Glucose test system Regulatory Class: Class II Product Code: NBW; JJX Dated: November 18, 2003 Received: November 20, 2003
Dear Ms. Cheng:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
3
Page 2 -
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device: or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97), You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
Steven Putman
Steven I. Gutman, M.D., M.B.A. Director Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
4
Page of
510(k) Number (if known): Ko32 029
BTg Smartest Glucose Test System Device Name:
Indications For Use:
The BTg Smartest Glucose test system is intended for use in the quantitative measurement of glucose in whole blood. It is intended for use by healthcare professionals and people with diabetes mellitus at home as an aid in monitoring the effectiveness of a diabetes control program. It is not intended for the diagnosis of or screening for diabets mellitus, and is not intended for use on neonates.
Concurrence of CDRH, Office of Device Evaluation (ODE)
(PLEASE DO NOT WRITE BELOW THIS LINE- CONTINUE ON ANOTHER PAGE)
Concurrence of CDRH, Office of Device Evaluation (ODE)
or
Prescription Use
(Per 21 CFR 801.109)
Over-The Counter Use
Carl C. Bnam / Jean Cooper, DVM
Division Sign-Off
Office of In Vit:ാ Diagnostic Device Evaluation and Safety
510(k) K032029